Fiedler, W., Cresta, S., Schulze-Bergkamen, H., Dosso, S. D., Weidmann, J., Tessari, A., . . . Gianni, L. (2018). Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ESMO open, 3(2), . https://doi.org/10.1136/esmoopen-2017-000303
Chicago-Zitierstil (17. Ausg.)Fiedler, Walter, et al. "Phase I Study of Tomuzotuximab, a Glycoengineered Therapeutic Antibody Against the Epidermal Growth Factor Receptor, in Patients with Advanced Carcinomas." ESMO Open 3, no. 2 (2018). https://doi.org/10.1136/esmoopen-2017-000303.
MLA-Zitierstil (9. Ausg.)Fiedler, Walter, et al. "Phase I Study of Tomuzotuximab, a Glycoengineered Therapeutic Antibody Against the Epidermal Growth Factor Receptor, in Patients with Advanced Carcinomas." ESMO Open, vol. 3, no. 2, 2018, https://doi.org/10.1136/esmoopen-2017-000303.